

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Books

Search PubMed for [] Preview Go Clear

Limits Preview/Index History Clipboard Details

- Search History will be lost after eight hours of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.
- Click on query # to add to strategy

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI (Cubby)

Search

Most Recent Queries

Time Result

#7 Search #1 and #4

17:01:29 1

#6 Search acute coronary events

17:01:19 4653

#3 Search #1 and #2

16:59:47 42

#2 Search atherosclerosis

16:58:01 94970

#1 Search (pla-2 or pla2) and inhibitors

16:57:50 3832

Clear History

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central



Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Oct 12 2005 11:14:01

[All Databases](#)[PubMed](#)[Nucleotide](#)[Protein](#)[Genome](#)[Structure](#)[OMIM](#)[PMC](#)[Journals](#)[Books](#)

Search for

[Limits](#)[Preview/Index](#)[History](#)[Clipboard](#)[Details](#)

Display Show Sort by Send to

All: 1 Review: 1

[About Entrez](#)[Text Version](#)[Entrez PubMed](#)[Overview](#)[Help | FAQ](#)[Tutorial](#)[New/Noteworthy](#)[E-Utilities](#)[PubMed Services](#)[Journals Database](#)[MeSH Database](#)[Single Citation Matcher](#)[Batch Citation Matcher](#)[Clinical Queries](#)[Special Queries](#)[LinkOut](#)[My NCBI \(Cubby\)](#)[Related Resources](#)[Order Documents](#)[NLM Mobile](#)[NLM Catalog](#)[NLM Gateway](#)[TOXNET](#)[Consumer Health](#)[Clinical Alerts](#)[ClinicalTrials.gov](#)[PubMed Central](#)

☐ 1: Curr Opin Pharmacol. 2001 Apr;1(2):121-5.

[Related Articles, Links](#)

Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target.

Macphee CH.

Department of Vascular Biology, SmithKline Beecham Pharmaceuticals, Harlow, Essex, UK. Colin_H_Macphee@sbphrd.com

The recognition that atherosclerosis represents an inflammatory disease has begun to shift interest towards novel therapies that could specifically target the underlying inflammatory component of atherogenesis. Like low-density lipoprotein, an ideal new drug target would be a modifiable plasma risk factor that not only reflects the ongoing inflammatory process but also actively promotes it. Lipoprotein-associated phospholipase A2, also known as platelet-activating factor acetylhydrolase, is a new risk factor that may have the potential to fulfil these requirements.

Publication Types:



- [Review](#)
- [Review, Tutorial](#)

PMID: 11714085 [PubMed - indexed for MEDLINE]

Display Show Sort by Send to

[Write to the Help Desk](#)[NCBI | NLM | NIH](#)[Department of Health & Human Services](#)[Privacy Statement | Freedom of Information Act | Disclaimer](#)

Oct 12 2005 11:14:01

[All Databases](#)[PubMed](#)[Nucleotide](#)[Protein](#)[Genome](#)[Structure](#)[OMIM](#)[PMC](#)[Journals](#)[Books](#)

Search for

[Limits](#) [Preview/Index](#) [History](#) [Clipboard](#) [Details](#)

Display

☐ All: 1 ☐ Review: 0

[About Entrez](#)[Text Version](#)[Entrez PubMed](#)[Overview](#)[Help | FAQ](#)[Tutorial](#)[New/Noteworthy](#)[E-Utilities](#)[PubMed Services](#)[Journals Database](#)[MeSH Database](#)[Single Citation Matcher](#)[Batch Citation Matcher](#)[Clinical Queries](#)[Special Queries](#)[LinkOut](#)[My NCBI \(Cubby\)](#)[Related Resources](#)[Order Documents](#)[NLM Mobile](#)[NLM Catalog](#)[NLM Gateway](#)[TOXNET](#)[Consumer Health](#)[Clinical Alerts](#)[ClinicalTrials.gov](#)[PubMed Central](#)

☐ 1: Farmaco. 2001 Jan-Feb;56(1-2):45-50.

[Related Articles, Links](#)

Lipoprotein-associated PLA2 inhibition--a novel, non-lipid lowering strategy for atherosclerosis therapy.

Leach CA, Hickey DM, Ife RJ, Macphee CH, Smith SA, Tew DG.

Glaxo SmithKline, New Frontiers Science Park, Harlow, Essex, UK. colin_leach-1@sbphrd.com

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a serine lipase that is associated with low density lipoprotein (LDL) in human plasma. Substrates include oxidised phosphatidylcholine (PC), which is hydrolysed by Lp-PLA2 to lyso-PC and oxidised fatty acids. Both products are bioactive and proinflammatory, and implicated in monocyte infiltration into the developing plaque, deposition of foam cells, and plaque progression and instability. Lp-PLA2 has recently been shown to be a risk factor for coronary events in previously asymptomatic, hypercholesterolaemic men. A series of azetidinones was designed as potent and selective inhibitors of this enzyme; SB-222657 inhibited release of the chemotactic cleavage products from oxidised LDL, and SB-244323 reduced atherosclerotic plaque development in a 3 month rabbit study. A series of pyrimidones has been designed from a screening hit, and nanomolar inhibitors identified. Oral efficacy in inhibiting plasma Lp-PLA2 in rabbits has been demonstrated with a variety of structural classes.

PMID: 11347966 [PubMed - indexed for MEDLINE]

Display

[Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)[Department of Health & Human Services](#)[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Oct 12 2005 11:14:01